Study blood markers in pancreatic IPMN
Part of Cancer clinical trials.
This study looks for “biomarkers,” meaning measurable signs in the blood, in people diagnosed with intraductal papillary mucinous neoplasm (IPMN). It aims to better understand what changes happen in this condition and may help future diagnosis or monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a clinician diagnosis of pancreatic IPMN
- You do not have another cancer diagnosis at the same time
- You are willing to sign the study consent form
- You do not have a mental health condition that affects thinking and cooperation
- You do not have serious blood diseases, and you are not on medications that could change blood test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why doctors decided to do surgery for a certain type of pancreatic cyst (IPMN) and how well patients did after. If you had surgery for an IPMN between 2015 and 2025, you may be able to help doctors learn more.
This study looks for new markers in the blood or tissues of people with a pancreatic condition called IPMN. The goal is to find better ways to predict if IPMN might turn into cancer and to help choose the best treatment.
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
This trial looks for markers in cyst fluid and tissue to help identify which IPMN growths are becoming invasive (spreading). It may help doctors decide who needs surgery.
This study follows patients with IPMN (a type of pancreatic growth) who are already getting regular imaging scans. Researchers want to understand whether changes in how well the pancreas makes digestive enzymes can help predict how the condition progresses and when intervention might be needed.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
Hear when a new Intraductal Papillary Mucinous Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.